

## MedDRA User Input Needed for Proposed Neoplasm SOC Changes (BRP7)

The MSSO encourages all MedDRA users, and especially those involved with oncology products in development or on the market, to review a set of spreadsheets that describe *potential changes* to terms in SOC *Neoplasms benign, malignant and unspecified (incl cysts and polyps)* (“Neoplasm SOC”). These proposed changes reflect recommendations arising from the 7<sup>th</sup> MedDRA Blue Ribbon Panel held in April 2011.

Please provide your feedback to the [MSSO Help Desk](#) by **Friday 13 April 2012**. An explanatory note and spreadsheets detailing the proposed changes can be found on the [MSSO Subscriber Web page](#) under “Announcements.”

The aim of this review is to provide the MSSO with feedback on the impact these changes could have on your MedDRA coded data (including medical history and indication data, as well as coded adverse event data). Your feedback will help the MedDRA Management Board and the MSSO determine how to implement these changes into MedDRA. We encourage high level comments (e.g., impact of demotion of “stage” terms) rather than feedback on specific terms.

Thank you in advance for your help with this effort to improve MedDRA.

The MSSO